Pure Australian Milk

BBY Limited (“*BBY*”) and Aetas Global Markets Limited (“*Aetas*”) have been mandated by Pure Australian Milk Limited (PAM) as Joint Lead Managers to the A$6 million Pure Australian Milk Group Milk Preference Shares...

Find out more

High Conviction Model Portfolio

The Australian Equities Model Portfolio has returned 21.3% annualized over 5 years.

Find out more

BBY NZ Products

Our specialist area in the markets covers Foreign Exchange, Commodities, Futures, CFD’s Exchange Traded Options, Exchange Traded Funds...

Find out more

Traders Dictionary

Stuck on some jargon? We cover the common terminology here in our comprehensive online stock market glossary.

Find out more

Institutional & Retail Research

The BBY Research Team has a combined experience of over 100 years in investment banking and equity research, covering over 120 stocks across all major sectors. BBY also offers its clients over 600 company profiles across the ASX and NZX.

Find out more

Media & Press

BBY is able to provide Australian and international media with access to our team of leading Research Analysts and select Senior Executives for commentary on market sectors, company results and company performance.

Find out more

Become a BBY Client Advisor

BBY is looking to increase its existing Australian and New Zealand Client Advisory business by offering an additional 90 seats.

Find out more

BBY News

Prospects for stem cell company skyrocket 193%

20 February 2015

Shares of Cynata Therapeutics Limited (ASX:CYP) skyrocketed 193% following the announcement on Thursday that its cutting edge stem cell technology has been validated by a key US biomanufacturing site. This stem cell and...

Read More

BBY Trend Barometer

Latest Tweets

BBY (NZ) Limited. All rights reserved (NZBN 9429034016398). Part of the BBY Group (BBY Limited. Participant of the Australian Stock Exchange Group. ABN 80 006 707 777 AFSL 238 095).